Asked last May by Ifop, the French say they have trouble identifying the origin of the drugs marketed in our country. They are 80% to know it badly, even very badly, an even greater proportion among the oldest people (85% among those over 65). In the context of public hospital orders, the environmental impact of drugs is only a concern for 20% of them (30% for those under 35), far behind the nationality of the pharmaceutical companies referenced by hospital establishments. 55% of the French people questioned preferred that the latter favor French and European manufacturers, a concept that has no real link with the location of their sites and their production methods. As for the criteria for the choice of drugs by doctors and pharmacists, 62% highlight their economic advantage for health insurance, compared to 38% who would maintain that health professionals focus on specialties presenting the most low carbon footprint. This ecological sensitivity is greater among those under 35 (49%) and higher education graduates (44%).
Promoting eco-responsible medicines
Sponsor of this survey, Chiesi chose to present its results on the occasion of World Environment Day, as part of a round table on the environmental impact of health industries. The first laboratory to have declared itself a “company with a mission”, this industrialist of Italian origin is making concrete commitments in order to achieve carbon neutrality by 2035. It is working in particular on the implementation of eco-responsibility agreements with its 70 suppliers. In the respiratory field, one of its therapeutic areas, the group is currently developing a new generation inhaler, equipped with a propellant gas headlight intended to limit its carbon footprint. French leaders want to go further and influence prescribing behavior by encouraging doctors to favor eco-responsible drugs.
To go further, discover all our studies of pharmacy-health sector.